Notably, unlike p300/CBP bromodomain inhibitors or BET inhibitors56,57, CBPD-409 did not cause thrombocytopenia or megakaryocyte loss58 (Extended Data Fig. 9f,g) or goblet cell depletion59–62 (Extended Data Fig. 9h). Here, EP300 is linked to Thrombocytopenia.